Ortho Biotech: Don't restrict coverage of antianemics

Article

The Bridgewater, N.J., firm maintains that cancer patients could be hurt by CMS' reduced coverage proposal for these antianemia agents.

Like Amgen, Ortho Biotech has taken issue with CMS' proposal to limit coverage of erythropoiesis-stimulating agents (ESAs). Ortho Biotech said CMS should pay heed to what the FDA has approved in its product labeling. The Bridgewater, N.J., firm maintains that cancer patients could be hurt by CMS' reduced coverage proposal for these antianemia agents, adding that others, such as medical associations, health professionals, and patients, have come to the same conclusion. To view the full statement from the maker of Procrit (epoetin alfa), check out

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series
Image Credit: jokekung - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.